Pharmaceutical segmentJohnson & Johnson’s (JNJ) Pharmaceutical segment is the company’s key revenue driver and accounted for 51.17% of the company’s total revenues in the first quarter. Darzalex, Stelara, Tremfya, and Imbruvica reported double-digit YoY revenue growth in the first quarter. To know more about the Pharmaceutical segment’s performance in the first quarter, please refer to Pharmaceutical Segment: A Key Revenue Driver for JNJ in Q1.Darzalex growth trendsDarzalex has been reporting a robust rise in market share across all lines of MM (multiple myeloma) therapy in the US as well as rapid penetration in ex-US markets. According to Johnson & Johnson’s first-quarter earnings conference call, these trends have pushed up the drug’s revenues YoY by 45.5% on a reported basis and 51.2% to $629 million in the first quarter.Stelara growth trendsImmunology drug Stelara reported worldwide sales of $1.40 billion, a YoY rise of 32.4% on a reported basis and 36.0% on an operational basis. According to Johnson & Johnson’s first-quarter earnings conference call, this performance was mainly driven by an eight percentage-point YoY increase in US market share in the Crohn’s disease indication.Tremfya growth trendsIts recently launched moderate-to-severe psoriasis drug, Tremfya, reported worldwide revenues of $217 million in the first quarter. According to Johnson & Johnson’s first-quarter earnings conference call, there were 31,000 patients using Tremfya at the end of the first quarter of 2019. Tremfya accounted for 6.9% of the psoriasis market in the US in the first quarter, a YoY rise of four percentage points. Tremfya is expected to benefit from head-to-head trials, which demonstrated its superior efficacy based on chosen endpoints over key competitors such as Cosentyx, Humira, and Stelara in the psoriasis indication.Imbruvica growth trendsA shared asset with AbbVie, Imbruvica reported revenues of $784 million for Johnson & Johnson, a YoY rise of 40.4% on an operational basis and 33.5% on a reported basis. This performance was driven by robust demand in the US and ex-US markets. According to Johnson & Johnson’s first quarter earnings conference call, Imbruvica has already become the leading player based on new patient share as well as total patient share in the chronic lymphocytic leukemia indication in the US.